mRNA vaccine against delta mutant strain of novel coronavirus and its preparation method and application

By developing mRNA vaccines against the delta mutant strain of the novel coronavirus, using the combination of delta S2-043 mRNA and liposome particles, the problem of insufficient immune response of existing vaccines to the mutant strain of the novel coronavirus and Omickron strains is solved. , achieving efficient neutralization activity and cross-protection effects.

CN115725613BActive Publication Date: 2024-11-12BEIJING NEOCURNA BIOTECHNOLOGY CORP +2
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202211145668.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-09-20
Publication Date
2024-11-12
Estimated Expiration
2042-09-20

AI Technical Summary

Technical Problem

The existing SARS-CoV-2 vaccine is difficult to effectively target mutations in the novel coronavirus delta mutant strain and Omickron strain, resulting in insufficient immune response and ineffective prevention and control of the ever-changing new coronavirus epidemic strain.

Method used

An mRNA vaccine against the delta mutant strain of the novel coronavirus was developed. By encoding the combination of delta S2-043 mRNA and liposome particles, an efficient nanolipid particle vaccine can express the correct conformation at a high level in the cell. Spike protein, induces high levels of neutralizing antibodies, has cross-neutralization activity against Delta and Omicron strains.

Benefits of technology

This vaccine not only has a high level of neutralization activity against the Delta strain, but also shows a high level of cross-neutralization activity against the Omicron strain, providing broad-spectrum immune prevention protection and having important clinical application value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure HDA0003855153340000011
    Figure HDA0003855153340000011
  • Figure HDA0003855153340000012
    Figure HDA0003855153340000012
Patent Text Reader

Abstract

The present invention provides a delta S2-043 mRNA for preparing a delta mutant strain of a novel coronavirus, and the sequence thereof is shown in SEQ ID NO.5. An mRNA vaccine prepared from the delta S2-043 mRNA and liposome particles is also provided. The present invention screens a delta S2-043 mRNA that has undergone appropriate mutations and in which transfected cells express a high level of a Spike protein with a correct conformation and binding force to hACE2. The mRNA vaccine prepared from the delta S2-043 mRNA has high immune efficacy against the delta mutant strain of the novel coronavirus, and the serum neutralizing antibodies induced by immunity have a high level of neutralizing activity not only against the Delta strain, but also against the Omicron strain, and will have a good clinical application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and specifically to an mRNA vaccine against a delta mutant strain of the novel coronavirus, and a preparation method and application thereof. Background Art

[0002] SARS-CoV-2 is a novel coronavirus. SARS-CoV-2 is an enveloped positive-strand RNA virus that needs to fuse with the host cell membrane to infect. The spike protein is the main envelope protein of SARS-CoV-2, which is composed of S1 and S2 subunits. S1 mainly contains the receptor binding domain (RBD), which is responsible for recognizing the cell's receptors. S2 contains the basic elements required for the membrane fusion process. The spike protein is responsible for the binding and membrane fusion of the virus and the host cell membrane receptors. It is an important site for host neutralizing antibodies and a key target for vaccine design. The surface S protein of the 2019 novel coronavirus enters the cell by recognizing the ACE2 protein of the human host. The cell receptor binding domain (RBD) of the S protein domain is directly involved in the recognition of the host receptor. Amino acid variations in this region can lead to changes in the species tropism and infection characteristics of the virus.

[0003] Delta is a variant of the coronavirus that was first discovered in India in October 2020. In May 2021, the World Health Organization named the B.1.617.2 variant of the coronavirus first discovered in India as the "Delta" variant. The Delta strain has spread to many countries and is still spreading rapidly. Delta has significantly benefited by improving its ability to infect human cells and spread. Compared with other variants, including the Alpha virus, the Delta virus reproduces faster and at higher levels in the respiratory tract of the infected person, which may exceed the initial immune response to the virus.

[0004] Delta and its descendants now account for the vast majority of COVID-19 cases worldwide. Most researchers expected these Delta strains to ultimately win out, but the emergence of Omicron has defied those predictions. Omicron contains more mutations than other variants, particularly in the spike region that recognizes host cells, and laboratory exploration and epidemiological studies are needed to fully understand the impact of these mutations.

[0005] The best hope for SARS-CoV-2 is that infection or vaccination will provide lifelong protection. Vaccines against SARS-CoV-2 could reduce the severity of the disease and slow its spread. How quickly SARS-CoV-2 evolves in response to the immune system will also determine whether the vaccine needs to be updated. Some evolutionary biologists expect that SARS-CoV-2 will eventually slow down to a more stable state of change. Other evolutionary biologists believe that while other respiratory viruses, including seasonal coronaviruses such as 229E, offer several potential futures for SARS-CoV-2, this virus could go in a completely different direction in the future. The future of SARS-CoV-2 may still be in the hands of humans, and getting as many people vaccinated as possible while vaccines are still very effective could prevent the virus from causing a new wave of outbreaks.

[0006] mRA vaccines introduce mRNA encoding disease-specific antigens into the body, and use the protein synthesis mechanism of host cells to produce antigens, thereby triggering an immune response. Usually, mRNA sequences of specific antigens can be constructed according to different diseases, which are encapsulated and transported into cells by new lipid nanocarrier particles. Then, human ribosomes are used to translate the mRNA sequences to produce disease antigen proteins, which are secreted and recognized by the body's immune system to produce immune responses, thereby achieving the effect of preventing diseases. mRNA vaccines are far superior to protein vaccines in terms of germinal center response, Tfh activation, neutralizing antibody production, specific memory B cells, and long-lived plasma cells. Scientists from various countries are committed to developing new, safe and effective anti-SARS-CoV-2 vaccines, especially mRNA vaccines for the more prevalent delta mutant strain. Summary of the invention

[0007] Based on this, the purpose of the present invention is to provide an mRNA vaccine against the delta mutant strain of the new coronavirus and its preparation method and application.

[0008] The technical solution to achieve the above purpose is as follows:

[0009] The first aspect of the present invention provides a method for preparing delta S2-043 mRNA for the delta mutant strain of the new coronavirus, the sequence of which is shown in SEQ ID NO.5.

[0010] A DNA molecule for preparing the delta S2-043 mRNA, the sequence of which is shown in SEQ ID NO.4.

[0011] A DNA molecule encoding the delta S2 protein shown in SEQ ID NO.2, whose sequence is shown in SEQ ID NO.3.

[0012] The present invention also provides the use of the above-mentioned delta S2-043 mRNA and the above-mentioned DNA molecule in the preparation of an mRNA vaccine against the delta mutant strain of the new coronavirus.

[0013] The second aspect of the present invention is to provide an mRNA vaccine against the delta mutant strain of the new coronavirus, which is prepared from the above-mentioned delta S2-043 mRNA and liposome particles.

[0014] The third aspect of the present invention is to provide a method for preparing the above-mentioned mRNA vaccine against the delta mutant strain of the new coronavirus, comprising the following steps:

[0015] The delta S2-043 mRNA is dissolved in sodium citrate buffer to form an aqueous phase;

[0016] The mass ratio of Dlin-MC3-DMA: DSPC: cholesterol: DMG-PEG2000 is 45-55: 7-12: 37-39: 1.2-1.8 to prepare an ethanol phase with anhydrous ethanol as solvent;

[0017] The aqueous phase and the ethanol phase are coated at a flow rate ratio of 2.5-4.5:1 and a total flow rate of 11-13 mL / min, and the nanolipid particles loaded with mRNA are collected and filtered and purified to obtain the result.

[0018] In some of the embodiments, the mass ratio of Dlin-MC3-DMA, DSPC, cholesterol, and DMG-PEG2000 is 49-51:9-11:38-39:1.4-1.6.

[0019] In some of the embodiments, coating was performed at a flow rate ratio of aqueous phase:alcohol phase = 3:1 and a total flow rate of 12 mL / min.

[0020] The fourth aspect of the present invention provides the use of the above-mentioned mRNA vaccine against the delta mutant strain of the new coronavirus in the preparation of immune drugs for preventing and treating new coronavirus infection.

[0021] Compared with the prior art, the present invention has the following beneficial effects:

[0022] The present invention has screened out a delta S2-043 mRNA that has undergone appropriate mutations and has a high level of Spike protein with the correct conformation expressed in transfected cells. The mRNA vaccine prepared from the delta S2-043 mRNA has high immune efficacy against the delta mutant strain of the new coronavirus. The immune-induced serum neutralizing antibodies not only have a high level of neutralizing activity against the Delta strain, but also have a high level of cross-neutralizing activity against the Omicron strain. It provides immune preventive protection for the prevention and control of the continuously mutated epidemic strains of the new coronavirus and has important clinical application value. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1A Plasmid map of Test 043-S2-tPA-pNeoCuall Amp(+) in Example 1.

[0024] Figure 1B Agarose gel electrophoresis results of the Test 043-S2-tPA-pNeoCuall Amp(+) linearized purified plasmid and the recombinant plasmid before enzyme digestion in Example 1.

[0025] Figure 2 Agarose gel electrophoresis results of delta S2-043 mRNA in Example 1.

[0026] Figure 3 The average fluorescence intensity of the Spike protein expressed by each mRNA in Example 1 and R001 binding.

[0027] Figure 4 The results of flow cytometry (BD, FACS Celesta) detection of the ability of the Spike protein expressed by delta S2-043 mRNA to bind to R001 and hACE2 in Example 1.

[0028] Figure 5 The results of delta S2-043 mRNA Western blot detection of molecular weight.

[0029] Figure 6 Delta S2-043 LNP Zeta potential results.

[0030] Figure 7 delta S2-043 LNP Zeta particle size results.

[0031] Figure 8 Cryo-EM image of delta S2-043 mRNA LNPLNP in Example 4.

[0032] Figure 9Serum antigen-specific antibody ELISA detection in Example 4.

[0033] Figure 10 The neutralization titer test results of the Spike pseudovirus expressing the Delta (B.1.617.2) strain in Example 5.

[0034] Figure 11 The neutralization titer test results of the Spike pseudovirus expressing the Omicron (BA.1) strain in Example 5. DETAILED DESCRIPTION

[0035] In order to facilitate the understanding of the present invention, the present invention will be described more fully below. The present invention can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present invention more thorough and comprehensive.

[0036] The experimental methods in the following examples without specifying specific conditions are usually carried out according to conventional conditions, such as the fourth edition of Molecular Cloning: A Laboratory Manual edited by Green and Sambrook, published in 2013, or according to the conditions recommended by the manufacturer. The various commonly used chemical reagents used in the examples are all commercially available products.

[0037] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those commonly understood by those skilled in the art to which the present invention belongs. The terms used in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used in the present invention includes any and all combinations of one or more of the related listed items.

[0038] Definitions To facilitate understanding of this technology, certain terms and phrases are defined below.

[0039] mRNA (Messenger RNA) is a type of single-stranded RNA that is transcribed from a strand of DNA as a template and carries genetic information and can guide protein synthesis.

[0040] Signal peptide: A short (5-30 amino acids in length) peptide chain that directs newly synthesized proteins into the secretory pathway.

[0041] LNP: Lipid nanoparticles, a type of lipid vesicle with a uniform lipid core, are widely used in the delivery of small molecules and nucleic acid drugs. They can encapsulate messenger ribonucleic acid (mRNA) encoding viral proteins, which helps transport viral proteins into cells and protect them from destructive enzymes.

[0042] Dlin-MC3-DMA:(6Z,9Z,28Z,31Z)-heptatriacont-6,9,28,31-tetraene-19-yl4-(dimethylamino)butanoate.

[0043] DMG-PEG2000:1,2-dimyristoyl-rac-glycero-3-methoxypolyethyleneglycol-2000 (1,2-dimyristoyl-rac-glycero-3-methoxypolyethyleneglycol-2000,DMG-PEG2000).

[0044] DSPC: Distearoylphosphatidylcholine.

[0045] SEQ ID NO.1

[0046] MFVFLVLLPLVSSQCVNLRTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPF LGVYYHKNNKSWMESGVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNEN GTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYN YKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPF QQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSRRRARSVASQSIIAYTMSLGAE NSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLG DIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQNVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFV SGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCCLKGCCSCGSCCKFDEDDSE PVLKGVKLHYT

[0047] SEQ ID NO.2

[0048] MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARQCVNLRTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLDVYYHKNNKSWMESGVYSSANNCTFEYV SQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSVLEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKC TLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTG CVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKK FLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSRGSASSVA SQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQ YGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSG WTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQNVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTT APAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKY EQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCCLKGCCSCGSCCKFDEDDSEPVLKGVKL HYT#

[0049] SEQ ID NO.3

[0050] ATGAAGAGAGGACTGTGCTGTGTGCTGCTGCTGTGTGGCGCCGTGTTTGTGAGCCCTAGCCAGGAGATCCACGCCAGATTCAGAAGAGGCGCCAGACAGTGCGTGAACCTGAGAACCAGAACCCAGCTGCCTCCTGCTTACACCAACAGCTTCACCAGAGGCGTGTACTACCCCGACAAGGTGTTCAGAAGCAGCGTGCT GCACAGCACCCAGGACCTGTTCCTGCCTTTCTTCAGCAACGTGACCTGGTTCCACGCCATCCACGTGAGCGGCACAAACGGCACAAAGAGATTCGACAACCCCGTGCTGCCCTTCAACGACGGAGTGTACTTC GCCAGCACAGAGAAGAGCAACATCATCCGGGGCTGGATCTTCGGCACAACCCTGGACAGCAAGACC CAGTCTCTGCTGATCGTGAACAACGCCACCAACGTGGTGATCAAGGTGTGCGAGTTCCAGTTCTGCAACGACCCCTTCCTGGACGTGTACTACCACAAGAACAACAAGAGCTGGATGGAGAGCGGCGTGTACA GCAGCGCCAACAACTGCACCTTCGAGTACGTGAGCCAGCCTTTCCTGATGGACCTGGAGGGCAAGCAGGGCAACTTCAAGAACCTGCGGGAGTTCGTGTTCAAGAACATCGACGGCTACTTCAAGATCTACAGC AAGCACACCCCTATCAACCTGGTGCGGGACCTGCCTCAGGGCTTCAGCGTGCTGGAGCCTCTGGTGGACCTGCCTATCGGCATCAACATCACACGGTTCCAGACACTGCTGGCCCTGCACAGAAGCTACCTGAC ACCTGGCGACAGCAGCAGCGGATGGACAGCTGGAGCTGCTGCCTACTACGTGGGCTACCTGCAGCCCAGAACATTCCTGCTGAAGTACAACGAGAACGGCACAATCACCGACGCCGTGGACTGCGCCCTGGACCCTCTGAGCGAGACAAAGTGCACCCTGAAGAGCTTCACCGTGGAGAAGGGCATCTACCAGACCAGCAACTTCCGGGTGCAGCCTACAGAGAGCATCGTGCGGTTCCCTAACATCACCAACCTGTGCCCTTTCGGC GAGGTGTTCAACGCCACAAGATTCGCCAGCGTGTACGCTTGGAACCGGAAGCGGATCAGCAACTGCGTGGCCGATTACAGCGTGCTGTACAACAGCGCCAGCTTCAGCACCTTCAAGTGCTACGGCGTGAGCCC TACCAAGCTGAACGACCTGTGCTTCACCAACGTGTACGCCGACAGCTTCGTGATCAGAGGAGACGAGGTGAGACAGATCGCCCCTGGCCAGACAGGCAAGATCGCCGACTACAACTACAAGCTGCCCGACGACT TCACAGGCTGTGTGATCGCCTGGAACAGCAACAACCTGGACAGCAAGGTGGGCGGCAACTACAACT ACCGGTACCGGCTGTTCCGGAAGAGCAACCTGAAGCCCTTCGAGCGGGACATCAGCACAGAGATCTACCAGGCCGGCAGCAAACCTTGCAACGGAGTGGAGGGCTTCAACTGCTACTTCCCTCTGCAGAGCTAC GGCTTCCAGCCTACAAACGGCGTGGGCTACCAGCCTTACAGAGTGGTGGTGCTGAGCTTCGAGCTGCTGCATGCCCCTGCTACAGTGTGCGGCCCTAAGAAGAGCACCAACCTGGTGAAGAACAAGTGCGTGAACTTCAACTTCAACGGCCTGACAGGCACAGGCGTGCTGACCGAGAGCAACAAGAAGTTCCTGCCTTTCCAGCAGTTCGGCAGAGACATCGCCGACACAACAGACGCCGTGAGAGACCCTCAGACACTGGAGATCCTGGACATCACACCTTGCAGCTTCGGCGGCGTGAGCGTGATCACCCCTGGCACAAACACAAGCAACCAGGTGGCCGTGCTGTACCAGGGCGTGAACTGCACAGAGGTGCCTGTGGCCATCCACGCTGACCAGC TGACACCTACCTGGAGAGTGTACAGCACAGGCAGCAACGTGTTCCAGACAAGAGCCGGCTGCCTGATCGGCGCTGAGCACGTGAACAACAGCTACGAGTGCGACATCCCTATCGGCGCTGGCATCTGCGCCAGC TACCAGACACAGACAAACAGCAGAGGCAGCGCCAGCAGCGTGGCAAGCCAGAGCATCATCGCCTACACAATGAGCCTGGGAGCCGAGAACAGCGTGGCCTACAGCAACAACAGCATCGCCATCCCCACCAACT TCACCATCAGCGTGACCACCGAGATCCTGCCCGTGAGCATGACAAAGACAAGCGTGGACTGCACCATGTACATCTGCGGCGACAGCACAGAGTGCAGCAACCTGCTGCTGCAGTACGGCAGCTTCTGCACACAG CTGAACAGAGCCCTGACAGGCATCGCTGTGGAGCAGGACAAGAACACCCAGGAGGTGTTCGCCCAGGTGAAGCAGATCTACAAGACCCCTCCCATCAAGGACTTCGGCGGCTTCAACTTCAGCCAGATCCTGC CTGACCCTAGCAAGCCTAGCAAGCGGAGCTTCATCGAGGACCTGCTGTTCAACAAGGTGACACTGGCCGACGCTGGCTTCATCAAGCAGTACGGCGACTGCCTGGGCGACATCGCCGCCAGAGATCTGATCTGCGCCCAGAAGTTCAACGGCCTGACAGTGCTGCCTCCTCTGCTGACAGACGAGATGATCGCCCAGTACA CAAGCGCCCTGCTGGCCGGCACAATCACAAGCGGCTGGACATTCGGCGCTGGCGCTGCTCTGCAGATCCCCTTCGCCATGCAGATGGCCTACAGATTCAACGGCATCGGCGTGACCCAGAACGTGCTGTACGAG AACCAGAAGCTGATCGCCAACCAGTTCAACAGCGCCATCGGCAAGATCCAGGACAGCCTGAGCAGCACAGCTTCTGCCCTGGGCAAGCTGCAGAACGTGGTGAACCAGAACGCCCAGGCCCTGAACACACTG GTGAAGCAGCTGAGCAGCAACTTCGGCGCCATCAGCAGCGTGCTGAACGACATCCTGAGCAGACTG GACCCTCCTGAGGCCGAGGTGCAGATCGACAGACTGATCACCGGCCGGCTGCAGTCTCTGCAGACATACGTGACACAGCAGCTGATCAGAGCCGCCGAGATTAGAGCCAGCGCCAACCTGGCTGCCACAAAGA TGAGCGAGTGCGTGCTGGGACAGAGCAAGAGAGTGGACTTCTGCGGCAAGGGATACCACCTGATGAGCTTCCCTCAGAGCGCTCCTCACGGCGTGGTGTTCCTGCACGTGACATACGTGCCTGCCCAGGAGAA GAACTTCACAACAGCCCCTGCCATCTGCCACGACGGCAAGGCCCACTTCCCTAGAGAGGGAGTGTTCGTGAGCAACGGCACACACTGGTTCGTGACACAGCGGAACTTCTACGAGCCCCAGATCATCACCACCGACAACACCTTCGTGAGCGGCAACTGCGACGTGGTGATCGGCATCGTGAACAACACCGTGTACGACCCTCTGCAGCCTGAGCTGGACAGCTTCAAGGAGGAGCTGGACAAGTACTTCAAGAACCACACCAGCCCTGACGTGGACCTGGGCGATATTAGCGGCATCAACGCCAGCGTGGTGAACATCCAGAAGGAGATCGACCGGCTGAACGAGGTGGCCAAGAACCTGAACGAGAGCCTGATCGACCTGCAGGAGCTGGGCAAGTAC GAGCAGTACATCAAGTGGCCCTGGTACATCTGGCTGGGCTTCATCGCCGGACTGATCGCCATCGTGATGGTGACCATCATGCTGTGCTGCATGACAAGCTGCTGCAGCTGCCTGAAGGGATGCTGCAGCTGTGGA AGCTGCTGCAAGTTCGACGAGGACGACAGCGAGCCTGTGCTGAAGGGCGTGAAGCTGCACTACACC TGATGA

[0051] SEQ IDNO.4

[0052] TAATACGACTCACTATAGGGAATAAACTAGTATTCTTCTGGTCCCCACAGACTCAGAGAGAACCCGCC ACCATGAAGAGAGGACTGTGCTGTGTGCTGCTGCTGTGTGGCGCCGTGTTTGTGAGCCCTAGCCAGG AGATCCACGCCAGATTCAGAAGAGGCGCCAGACAGTGCGTGAACCTGAGAACCAGAACCCAGCTGCCTCCTGCTTACACCAACAGCTTCACCAGAGGCGTGTACTACCCCGACAAGGTGTTCAGAAGCAGCGT GCTGCACAGCACCCAGGACCTGTTCCTGCCTTTCTTCAGCAACGTGACCTGGTTCCACGCCATCCACGTGAGCGGCACAAACGGCACAAAGAGATTCGACAACCCCGTGCTGCCCTTCAACGACGGAGTGTACTT CGCCAGCACAGAGAAGAGCAACATCATCCGGGGCTGGATCTTCGGCACAACCCTGGACAGCAAGACCCAGTCTCTGCTGATCGTGAACAACGCCACCAACGTGGTGATCAAGGTGTGCGAGTTCCAGTTCTGC AACGACCCCTTCCTGGACGTGTACTACCACAAGAACAACAAGAGCTGGATGGAGAGCGGCGTGTAC AGCAGCGCCAACAACTGCACCTTCGAGTACGTGAGCCAGCCTTTCCTGATGGACCTGGAGGGCAAGCAGGGCAACTTCAAGAACCTGCGGGAGTTCGTGTTCAAGAACATCGACGGCTACTTCAAGATCTACAG CAAGCACACCCCTATCAACCTGGTGCGGGACCTGCCTCAGGGCTTCAGCGTGCTGGAGCCTCTGGTGGACCTGCCTATCGGCATCAACATCACACGGTTCCAGACACTGCTGGCCCTGCACAGAAGCTACCTGA CACCTGGCGACAGCAGCAGCGGATGGACAGCTGGAGCTGCTGCCTACTACGTGGGCTACCTGCAGCCCAGAACATTCCTGCTGAAGTACAACGAGAACGGCACAATCACCGACGCCGTGGACTGCGCCCTGGACCCTCTGAGCGAGACAAAGTGCACCCTGAAGAGCTTCACCGTGGAGAAGGGCATCTACCAGACCAGCAACTTCCGGGTGCAGCCTACAGAGAGCATCGTGCGGTTCCCTAACATCACCAACCTGTGCCCTTTCGG CGAGGTGTTCAACGCCACAAGATTCGCCAGCGTGTACGCTTGGAACCGGAAGCGGATCAGCAACTGCGTGGCCGATTACAGCGTGCTGTACAACAGCGCCAGCTTCAGCACCTTCAAGTGCTACGGCGTGAGCC CTACCAAGCTGAACGACCTGTGCTTCACCAACGTGTACGCCGACAGCTTCGTGATCAGAGGAGACGAGGTGAGACAGATCGCCCCTGGCCAGACAGGCAAGATCGCCGACTACAACTACAAGCTGCCCGACGA CTTCACAGGCTGTGTGATCGCCTGGAACAGCAACAACCTGGACAGCAAGGTGGGCGGCAACTACAACTACCGGTACCGGCTGTTCCGGAAGAGCAACCTGAAGCCCTTCGAGCGGGACATCAGCACAGAGATC TACCAGGCCGGCAGCAAACCTTGCAACGGAGTGGAGGGCTTCAACTGCTACTTCCCTCTGCAGAGCT ACGGCTTCCAGCCTACAAACGGCGTGGGCTACCAGCCTTACAGAGTGGTGGTGCTGAGCTTCGAGCTGCTGCATGCCCCTGCTACAGTGTGCGGCCCTAAGAAGAGCACCAACCTGGTGAAGAACAAGTGCGTG AACTTCAACTTCAACGGCCTGACAGGCACAGGCGTGCTGACCGAGAGCAACAAGAAGTTCCTGCCTTTCCAGCAGTTCGGCAGAGACATCGCCGACACAACAGACGCCGTGAGAGACCCTCAGACACTGGAGATCCTGGACATCACACCTTGCAGCTTCGGCGGCGTGAGCGTGATCACCCCTGGCACAAACACAAGCAACCAGGTGGCCGTGCTGTACCAGGGCGTGAACTGCACAGAGGTGCCTGTGGCCATCCACGCTGACCA GCTGACACCTACCTGGAGAGTGTACAGCACAGGCAGCAACGTGTTCCAGACAAGAGCCGGCTGCCTGATCGGCGCTGAGCACGTGAACAACAGCTACGAGTGCGACATCCCTATCGGCGCTGGCATCTGCGCC AGCTACCAGACACAGACAAACAGCAGAGGCAGCGCCAGCAGCGTGGCAAGCCAGAGCATCATCGCCTACACAATGAGCCTGGGAGCCGAGAACAGCGTGGCCTACAGCAACAACAGCATCGCCATCCCCACCA ACTTCACCATCAGCGTGACCACCGAGATCCTGCCCGTGAGCATGACAAAGACAAGCGTGGACTGCACCATGTACATCTGCGGCGACAGCACAGAGTGCAGCAACCTGCTGCTGCAGTACGGCAGCTTCTGCACACAGCTGAACAGAGCCCTGACAGGCATCGCTGTGGAGCAGGACAAGAACACCCAGGAGGTGTTCGCC CAGGTGAAGCAGATCTACAAGACCCCTCCCATCAAGGACTTCGGCGGCTTCAACTTCAGCCAGATCCTGCCTGACCCTAGCAAGCCTAGCAAGCGGAGCTTCATCGAGGACCTGCTGTTCAACAAGGTGACACT GGCCGACGCTGGCTTCATCAAGCAGTACGGCGACTGCCTGGGCGACATCGCCGCCAGAGATCTGATCTGCGCCCAGAAGTTCAACGGCCTGACAGTGCTGCCTCCTCTGCTGACAGACGAGATGATCGCCCAGT ACACAAGCGCCCTGCTGGCCGGCACAATCACAAGCGGCTGGACATTCGGCGCTGGCGCTGCTCTGCAGATCCCCTTCGCCATGCAGATGGCCTACAGATTCAACGGCATCGGCGTGACCCAGAACGTGCTGTACGAGAACCAGAAGCTGATCGCCAACCAGTTCAACAGCGCCATCGGCAAGATCCAGGACAGCCTGAGCA GCACAGCTTCTGCCCTGGGCAAGCTGCAGAACGTGGTGAACCAGAACGCCCAGGCCCTGAACACACTGGTGAAGCAGCTGAGCAGCAACTTCGGCGCCATCAGCAGCGTGCTGAACGACATCCTGAGCAGAC TGGACCCTCCTGAGGCCGAGGTGCAGATCGACAGACTGATCACCGGCCGGCTGCAGTCTCTGCAGACATACGTGACACAGCAGCTGATCAGAGCCGCCGAGATTAGAGCCAGCGCCAACCTGGCTGCCACAAAG ATGAGCGAGTGCGTGCTGGGACAGAGCAAGAGAGTGGACTTCTGCGGCAAGGGATACCACCTGATGAGCTTCCCTCAGAGCGCTCCTCACGGCGTGGTGTTCCTGCACGTGACATACGTGCCTGCCCAGGAGA AGAACTTCACAACAGCCCCTGCCATCTGCCACGACGGCAAGGCCCACTTCCCTAGAGAGGGAGTGTTCGTGAGCAACGGCACACACTGGTTCGTGACACAGCGGAACTTCTACGAGCCCCAGATCATCACCACC GACAACACCTTCGTGAGCGGCAACTGCGACGTGGTGATCGGCATCGTGAACAACACCGTGTACGACCCTCTGCAGCCTGAGCTGGACAGCTTCAAGGAGGAGCTGGACAAGTACTTCAAGAACCACACCAGCC CTGACGTGGACCTGGGCGATATTAGCGGCATCAACGCCAGCGTGGTGAACATCCAGAAGGAGATCGACCGGCTGAACGAGGTGGCCAAGAACCTGAACGAGAGCCTGATCGACCTGCAGGAGCTGGGCAAGTACGAGCAGTACATCAAGTGGCCCTGGTACATCTGGCTGGGCTTCATCGCCGGACTGATCGCCATCGTGA TGGTGACCATCATGCTGTGCTGCATGACAAGCTGCTGCAGCTGCCTGAAGGGATGCTGCAGCTGTGGAAGCTGCTGCAAGTTCGACGAGGACGACAGCGAGCCTGTGCTGAAGGGCGTGAAGCTGCACTACAC CTGATGA CTGGTACTGCATGCACGCAATGCTAGCTGCCCCTTTCCCGTC CTGGGTACCCCGAGTCTCCCCCGACCTCGGGTCCCAGGTATGCTCCCACCTCCACCTGCCCCACTCACCACCTCTGC TAGTTCCAGACACCTCCCAAGCACGCAGCAATGCAGCTCAAAACGCTTAGCCTAGCCACACCCCCACGGGAAACAGC AGTGATTAACCTTTAGCAATAAACGAAAGTTTAACTAAGCTATACTAACCCCAGGGTTGGTCAATTTCGTGCCAGCC ACACCCTGGAGCTAGCCTCGAGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGCATATGACTAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

[0053] SEQ IDNO.5

[0054] GGGAAUAAACUAGUAUUCUUCUGGUCCCCACAGACUCAGAGAGAACCCGCCACCAUGAAGAGAG GACUGUGCUGUGUGCUGCUGCUGUGUGGCCGGUGUUUGUGAGCCCUAGCCCAGGAGAUCCACGCCAGUGCGUGAACCUGAGAACCAGCUGGCCUUGCUU ACACCAACACAUCACGUCAGGGCGGUGUAUACCCCACAAGGUGCUGCCA AGCACCCAGGACCUGUUCCUGCCUUUCUUCAGCAACGUGACCUGGGUUCCACGCCACGUGAGCGGCACAAACGGCACAAAGAGAUUCGACAACCCGUGCUGCCUUCAACGACGGAGGUUACUUCG CCAGCACAGAGAAGCAACAUCAUCCGGGGCUGGAUCUUCGGCACACAACCCCUGGACACGUCUGUACUCUGCUGAUCGUGAACAACGCCACCAACGUGGUUGCGAGUUCCAGUUCCAGUUCAGUUCCU GCAACGACCCCUUCCUGGACGUGUACCUACCACAAGAACAAGAGCCUGGAGCGCGGUUACACACAACAGACCUGCCACCACCUUCAGUCCU GCAAGCAGGGCAACUUCAAGAACCUGCGGGAGUUCGUUUCAAGAACAUCGACGGCUACUUCAAGAUCUACAGCAAGCACACCCCUAUCAACCUGGUGCGGAGCUGCCUCAGGCUUCAGCGUGCUGG AGCCUCUGGUGGACCUGCCUAUCGGCAUCAACAUCACACACAGGUUCCACACUGGCUGGCCCUGCCACAGAAGCUACCUGACACCUGGCGACACAGCGAUGGACACACGGACUGGAGCUGCCUACCUACG UGGGCUACCUAGCACCCAGAACAUUCCUGCUGCCUGAGCGAAGUACAACGAGACGGCACAAUCACCGACGCGGUGGACUGCGCCUGGACCCUCUGAGCCAGAGACAAAGUGCACAAGUCACCGCGUGGACUGCGCCUUGGACCCUCUGUGAGCGACACAAAGUGCACAAGUCACCUUGCAAGAUCACCAGGGCAUCUACCAGACCAGCAACUUCCGGGUGCAGCCUACAGAGAGCAUCGUGCGGUUCCCUAACAUCACCAACCUGUGCCCUUUCGGCGAGGUGUUCAACGCCACAAGAUUCGCCAGCGUGUACGCUUG GAACCGGAAGCGGAUCAGCAACUGCGUGGCCGAUUACAGCGUGCUGUACAACAGCGCCAGCUUCAGCACCUUCAAGUGCUACGGCGUGAGCCCUACCAAGCUGAACGACCUGUGCUUCACCAACGUGUA CGCCGACAGCUUCGUGAUCAGAGGAGACGAGGUGAGACAGAUCGCCCCUGGCCAGACAGGCAAGAUCGCCGACUACAACUACAAGCUGCCCGACGACUUCACAGGCUGUGUGAUCGCCUGGAACAGCAA CAACCUGGACAGCAAGGUGGGCGGCAACUACAACUACCGGUACCGGCUGUUCCGGAAGAGCAACCUGAAGCCCUUCGAGCGGGACAUCAGCACAGAGAUCUACCAGGCCGGCAGCAAACCUUGCAACGGA GUGGAGGGCUUCAACUGCUACUUCCCUCUGCAGAGCUACGGCUUCCAGCCUACAAACGGCGUGGGCUACCAGCCUUACAGAGUGGUGGUGCUGAGCUUCGAGCUGCUGCAUGCCCCUGCUACAGUGUGC GGCCCUAAGAAGAGCACCAACCUGGUGAAGAACAAGUGCGUGAACUUCAACUUCAACGGCCUGACAGGCACAGGCGUGCUGACCGAGAGCAACAAGAAGUUCCUGCCUUUCCAGCAGUUCGGCAGAGA CAUCGCCGACACAACAGACGCCGUGAGAGACCCUCAGACACUGGAGAUCCUGGACAUCACACCUUGCAGCUUCGGCGGCGUGAGCGUGAUCACCCCUGGCACAAACACAAGCAACCAGGUGGCCGUGCUGUACCAGGGCGUGAACUGCACAGAGGUGCCUGUGGCCAUCCACGCUGACCAGCUGACACCUACCUGGAGAGUGUACAGCACAGGCAGCAACGUGUUCCAGACAAGAGCCGGCUGCCUGAUCGGCGCUGAG CACGUGAACAACAGCUACGAGUGCGACAUCCCUAUCGGCGCUGGCAUCUGCGCCAGCUACCAGACACAGACAAACAGCAGAGGCAGCGCCAGCAGCGUGGCAAGCCAGAGCAUCAUCGCCUACACAAUGA GCCUGGGAGCCGAGAACAGCGUGGCCUACAGCAACAACAGCAUCGCCAUCCCCACCAACUUCACC AUCAGCGUGACCACCGAGAUCCUGCCCGUGAGCAUGACAAAGACAAGCGUGGACUGCACCAUGUACAUCUGCGGCGACAGCACAGAGUGCAGCAACCUGCUGCUGCAGUACGGCAGCUUCUGCACACAG CUGAACAGAGCCCUGACAGGCAUCGCUGUGGAGCAGGACAAGAACACCCAGGAGGUGUUCGCCC AGGUGAAGCAGAUCUACAAGACCCCUCCCAUCAAGGACUUCGGCGGCUUCAACUUCAGCCAGAUCCUGCCUGACCCUAGCAAGCCUAGCAAGCGGAGCUUCAUCGAGGACCUGCUGUUCAACAAGGUGAC ACUGGCCGACGCUGGCUUCAUCAAGCAGUACGGCGACUGCCUGGGCGACAUCGCCGCCAGAGAUCUGAUCUGCGCCCAGAAGUUCAACGGCCUGACAGUGCUGCCUCCUCUGCUGACAGACGAGAUGAUC GCCCAGUACACAAGCGCCCUGCUGGCCGGCACAAUCACAAGCGGCUGGACAUUCGGCGCUGGCGCUGCUCUGCAGAUCCCCUUCGCCAUGCAGAUGGCCUACAGAUUCAACGGCAUCGGCGUGACCCAGAACGUGCUGUACGAGAACCAGAAGCUGAUCGCCAACCAGUUCAACAGCGCCAUCGGCAAGAUCCAGGACAGCCUGAGCAGCACAGCUUCUGCCCUGGGCAAGCUGCAGAACGUGGUGAACCAGAACGCCCA GGCCCUGAACACACUGGUGAAGCAGCUGAGCAGCAACUUCGGCGCCAUCAGCAGCGUGCUGAACGACAUCCUGAGCAGACUGGACCCUGAGGCCGAGGUGCAGAUCGACAGACUGAUCACCGGCCGG CUGCAGUCUCUGCAGACAUACGUGACACAGCAGCUGAUCAGAGCCGCCGAGAUUAGAGCCAGCGCCAACCUGGCUGCCACAAAGAUGAGCGAGUGCGUGCUGGGACAGAGCAAGAGAGUGGACUUCUGCGGCAAGGGAUACCACCUGAUGAGCUUCCCUCAGAGCGCUCCUCACGGCGUGGUGUUCCUGCACGUGACAUACGUGCCUGCCCAGGAGAAGAACUUCACAACAGCCCCUGCCAUCUGCCACGACGGCAAGG CCCACUUCCCUAGAGAGGGAGUGUUCGUGAGCAACGGCACACACUGGUUCGUGACACAGCGGAACUUCUACGAGCCCCAGAUCAUCACCACCACCGACAACACCUUCGUGAGCGGCAACUGCGACGUGGUGA UCGGCAUCGUGAACAACACCGUGUACGACCCUCUGCAGCCUGAGCUGGACAGCUUCAAGGAGGAGCUGGACAAGUACUUCAAGAACCACACCAGCCCUGACGUGGACCUGGGCGAUAUUAGCGGCAUC AACGCCAGCGUGGUGAACAUCCAGAAGGAGAUCGACCGGCUGAACGAGGUGGCCAAGAACCUGAACGAGAGCCUGAUCGACCUGCAGGAGCUGGGCAAGUACGAGCAGUACAUCAAGUGGCCCUGGUACAUCUGGCUGGGCUUCAUCGCCGGACUGAUCGCCAUCGUGAUGGUGACCAUCAUGCUGUGCUGCAUGACAAGCUGCUGCAGCUGCCUGAAGGGAUGCUGCAGCUGUGGAAGCUGCUGCAAGUUCGACG AGGACGACAGCGAGCCUGUGCUGAAGGGCGUGAAGCUGCACUACACCUGAUGA CUGGUACUGCAUGCACGCAAUGCUAGCUGCCCCUUUCCCGUCCUGGGUACCCCGAGUCUC CCCCGACCUCGGGUCCCAGGUAUGCUCCCACCUCCACCUGCCCCACUCACCACCUCUGCUAGUUCCAGACACCUCCC AAGCACGCAGCAAUGCAGCUCAAAACGCUUAGCCUAGCCACACCCCCACGGGAAACAGCAGUGAUUAACCUUUAGCA AUAAACGAAAGUUUAACUAAGCUAUACUAACCCCAGGGUUGGUCAAUUUCGUGCCAGCCACACCCUGGAGCUAGCCU CGAGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGCAUAUGACUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

[0055] The present invention will be further described in detail below with reference to the accompanying drawings and specific embodiments.

[0056] Embodiment 1

[0057] 1. Construction of recombinant plasmid

[0058] According to the Spike protein sequence of the Delta mutant strain of the novel coronavirus in Sequence 1 (SEQ ID NO.1), the 984th amino acid lysine (K) in Sequence 1 was mutated to proline (P), and the 985th amino acid valine (V) was mutated to proline; the 680th amino acid arginine (R) was mutated to glycine (G), the 681st amino acid arginine (R) was mutated to serine (S), and the 683rd amino acid serine (S) was mutated to arginine (R). As shown in Sequence 1, the 1st to 13th amino acids are signal peptides. Experiments have confirmed that replacing the signal peptide sequence with the tPA signal peptide sequence can show the promotion of protein expression level. The protein is named delta S2 protein, as shown in Sequence 2 (SEQ ID NO.2). The DNA sequences encoding the above proteins were codon optimized to obtain 8 DNA sequences, namely delta S2-037 (SEQ ID NO.6), delta S2-043 (SEQ ID NO.7), deltaS2-44 (SEQ ID NO.8), delta S2-46 (SEQ ID NO.9), delta S2-48 (SEQ ID NO.10), deltaS2-49 (SEQ ID NO.11), delta S2-51 (SEQ ID NO.12), and delta S2-53 (SEQ ID NO.13). The DNA molecules shown in the above sequences were inserted between the 5'UTR and 3'UTR sequences of the pNeoCura-Bvac plasmid vector by homologous recombination to obtain a recombinant plasmid.

[0059] 2. Preparation of mRNA

[0060] The following description takes the preparation of delta S2-043 mRNA as an example.

[0061] 1. Linearized Template Preparation

[0062] Take the recombinant plasmid Test 043-S2-tPA-pNeoCuall Amp(+) (see the plasmid map for details) Figure 1A ), restriction endonuclease BspQ I was used for enzyme digestion, and the linearized plasmid was recovered and purified using VAHTS DNA Clean Beads (Novozyme, N411-01). The agarose gel electrophoresis results of the linearized purified plasmid and the recombinant plasmid before enzyme digestion are shown in Figure 1B .

[0063] 2. RNA obtained by in vitro transcription

[0064] RNA was obtained by in vitro transcription using the in vitro transcription kit T7 High Yield RNA Transcription Kit (N1-Me-PseudoUTP) (Novozyme, DD4202), and RNA was purified using VAHTS RNA Clean Beads (Vazyme, N412-01).

[0065] 5. Capping and purification

[0066] The purified RNA was capped using the capping kit mRNA Cap 2'-O-Methyltransferase (Novozyme, DD4110). The capped RNA was purified using VAHTS RNA Clean Beads (Vazyme, catalog number: N412-01) to obtain delta S2-043 mRNA. The results of agarose gel electrophoresis are shown in Figure 2 .

[0067] 3. In vitro mRNA expression

[0068] The codon-optimized sequences were prepared as mRNA and transfected into HEK293T. After 24 hours of transfection, the cells were centrifuged at 1000g for 10 minutes, and the cells were collected and incubated with monoclonal neutralizing antibodies R001 (Sino Biological, 40592-R001) and hACE2 (Sino Biological, 10108-H02H) against SARS-CoV-2 Spike protein, respectively. The mean fluorescence intensity (MFI) of the Spike protein expressed on the cell surface binding to R001 was detected by flow cytometry (BD, FACSCelesta). In vitro mRNA expression showed that the expression level of sequence mRNA delta S2-043 was significantly higher than that of other optimized sequences (see the results). Figure 3 ). The DNA molecule of the mRNA sequence delta S2-043 is shown in Sequence 3 (SEQ ID NO.3), encoding delta S2 protein.

[0069] The DNA sequence delta S2-043 (SEQ ID NO.3) was inserted into the 5'UTR and 3'UTR sequences of the pNeoCura-Bvac plasmid vector by homologous recombination to obtain a DNA molecule as shown in Sequence 4 (SEQ ID NO.4). In Sequence 4, nucleotides 1-19 constitute the T7 promoter, nucleotides 20-71 constitute the 5'UTR, nucleotides 72-3950 encode the delta S2 protein, nucleotides 3954-4242 constitute the 3'UTR, and nucleotides 4243-4352 constitute the segmented Poly A.

[0070] In the reverse transcription system, UTP is replaced by Pseudo-UTP (pseudo-uridine), and the DNA molecule shown in sequence 4 is transcribed to obtain the mRNA shown in sequence 5 of the sequence table (SEQ ID NO.5, U represents pU). The mRNA shown in sequence 5 is named delta S2-043 mRNA. delta S2-043 mRNA is translated to obtain delta S2 protein.

[0071] Example 2. In vitro expression of delta S2-043 mRNA and verification of protein characteristics

[0072] 1. HEK293T cell plating

[0073] Cells were seeded in 24-well plates (2.5-3×10 5 / well), and cultured in DMEM medium (Thermo Fisher Scientific) containing 10% serum and 1% double antibody at 37°C, 5% CO2 for 16-18 hours. The cell density reached 80% confluency before transfection.

[0074] 2. Transfection

[0075] The medium was replaced with serum-free Opti-MEM (Therm

[0076] o Fisher Scientific), 1 hour later, GFP mRNA (encoding green fluorescent protein GFP mRNA, control mRNA) and delta S2-043 mRNA (0.3ug or 1μg RNA / well) were incubated with Lipofectamine TM Messenger MAX TM The cells were transfected with a transfection reagent (Thermo Fisher Scientific) and, after culturing for 6 hours, the culture medium was replaced with DMEM medium (Thermo Fisher Scientific) containing 10% serum and 1% penicillin-streptomycin, and the culture was continued for 24 hours.

[0077] 3. Conformation verification of F protein expressed in delta S2-043 mRNA transfected cells and hACE2 binding assay

[0078] The cells were transfected with delta S2-043 mRNA (SEQ ID NO.5) for 24 hours, centrifuged at 1000g for 10 minutes, and the cells were collected and incubated with monoclonal neutralizing antibodies R001 (Sino Biological, 40592-R001) and hACE2 (Sino Biological, 10108-H02H) against SARS-CoV-2 Spike protein, respectively. Flow cytometry (BD, FACS Celesta) was used to detect the binding ability of Spike protein expressed on the cell surface with R001 and hACE2 (the results are shown in the attached Figure 4 ). The results showed that delta S2-043mRNA transfected cells expressed high levels of Spike protein with correct conformation and binding ability to hACE2.

[0079] 4. Protein molecular weight verification

[0080] After lysing the cells 24 hours after transfection, SDS-PAGE was performed, and then Western blot was performed. The primary antibody used in Western blot was the monoclonal neutralizing antibody R001 (SinoBiological, 40592-R001) (Sino Biological, 40589-T62) against SARS-CoV-2 Spike protein. Western Blot showed that the expected molecular weight (150-200Kda) was detected between 130kda-250Kda, indicating that the delta S2-043 mRNA transfected cells expressed the full-length Spike protein. The results are shown in Figure 5 .

[0081] Example 3. Preparation of delta S2-043 mRNA LNP (lipid nanoparticles)

[0082] 1. Dissolve the prepared delta S2-043 mRNA on ice, dilute to 100 ng / ul with 50 mM sodium citrate buffer, and prepare the ethanol phase using anhydrous ethanol as solvent, and prepare according to the mass ratio of Dlin-MC3-DMA: DSPC: cholesterol: DMG-PEG2000 = 50:10:38.5:1.5, so that the concentration of Dlin-MC3-DMA in the ethanol phase is 5.62 mg / ml and the total liposome concentration is 10.28 mg / ml. (Dlin-MC3-DMA: Avituo (Shanghai) Pharmaceutical Technology Co., Ltd., CAS No.: O02006; DSPC: Avituo (Shanghai) Pharmaceutical Technology Co., Ltd., CAS No.: S01005; CHO-HP (cholesterol): Avituo (Shanghai) Pharmaceutical Technology Co., Ltd., CAS No.: O01001; DMG-PEG2000: Avituo (Shanghai) Pharmaceutical Technology Co., Ltd., CAS No.: O02005).

[0083] 2. The aqueous phase and the ethanol phase were coated with a nano-drug preparation system (INano L, Maianna (Shanghai) Instrument Technology Co., Ltd.) at a flow rate ratio of 3:1, and a total flow rate of 12 mL / min, and LNP was collected. The collected LNP was diluted 3 times with RNase-free water and placed in a 100 kd dialysis bag, and then the dialysis bag was placed in 1XPBS with 200 times the volume of LNP for dialysis, with a magnetic stirrer at 300 rpm and room temperature for 18 hours; the LNP collected in the dialysis bag was sterilized and filtered using a 0.22 um filter membrane; the filtered LNP was centrifuged using a 100 kd ultrafiltration tube at 3000 rpm and 4°C for 90 minutes, and the LNP in the ultrafiltration tube was collected. The residual LNP in the tube was rinsed with 1X PBS, and the mixture with the previous LNP was delta S2-043 LNP, which was stored at 2-8°C in the dark.

[0084] 3. Take delta S2-043 LNP and use nanoparticle size measuring instrument (Litesizer 500, Anton Paar) to detect PDI, particle size, and Zeta potential; particle size: 112nm; PDI: 15.3%; Zeta potential: 40.8mV. This shows that delta S2-043 LNP has a stable structure. Particle size results are shown in Figure 6 , the potential detection results are shown in Figure 7 .

[0085] 4. The delta S2-043 LNP was taken and the encapsulation efficiency was calculated using Quant-iT RiboGreen RNA Assay Kit (ThermoFisher Scientific). The encapsulation efficiency was 95.7%.

[0086] 5. Take delta S2-043 LNP and observe the LNP morphology and structure using cryo-electron microscopy, which shows that delta S2-043 LNP has a uniform spherical morphology and structure. Figure 8 .

[0087] Example 4. Evaluation of the immune efficacy of delta S2-043 mRNA vaccine

[0088] 1. Immunization regimen

[0089] Female BABL / c mice aged 6-8 weeks were randomly divided into 4 groups: negative control group (empty LNP), delta S2-043 mRNA LNP low-dose group, delta S2-043 mRNA LNP medium-dose group, and delta S2-043 mRNA LNP high-dose group. Each group of mice was immunized by intramuscular injection on the first day (Prime) and the 21st day (Boost) of the experiment, with an immunization volume of 50 μL.

[0090]

[0091] The immunization dose of each dose group of delta S2-043 mRNA LNP is the dose of RNA.

[0092] 2. Serum antigen-specific antibody detection

[0093] On the 14th day (14 days post-Prime) and the 35th day (14 days post-Boost) of the experiment, blood was collected from the mouse retro-orbital venous plexus, and serum samples were separated and inactivated by heating at 56°C for 30 minutes. The inactivated serum was gradiently diluted with PBS buffer to obtain the test serum samples. The antigen-specific antibodies in the mouse serum were detected using ELISA kit (Vazyme, catalog number: DD3209-01). Three replicate wells were set for each well of the test serum sample. For specific operations, refer to the instructions provided by the merchant. ELISA results are shown in Fig. 9 The results showed that delta S2-043 mRNA LNP in each dose group induced the production of high titer anti-delta RBD specific IgG antibodies in mice after the first immunization (Prime). The antibody titer increased by 10-100 times 14 days after Boost. The amount of antibody produced by the high dose group was significantly higher than that of the low dose group. No antibody was produced in the negative control group.

[0094] 3. Pseudovirus neutralizing antibody titer detection

[0095] The inactivated serum of mice isolated on the 35th day of the experiment (14 days post-Boost) was used to detect the neutralizing antibody titer of the mouse immune serum against the delta strain or the Omicron strain using a pseudovirus system based on HIV expressing the Delta (B.1.617.2) strain Spike or the Omicron (BA.1) strain Spike. The results of the half neutralization titer (pNT50) are shown in Fig.10 (Neutralization titer of pseudovirus expressing Delta (B.1.617.2) strain Spike) and Fig.11(Expressing the neutralization titer of the Spike pseudovirus of the Omicron (BA.1) strain). The results showed that delta S2-043 mRNA LNP induced the production of high-titer neutralizing antibodies against the Delta strain, and the neutralizing antibodies produced by the high-dose group were significantly higher than those produced by the low-dose group. delta S2-043 mRNA LNP induced mice to produce high-titer neutralizing antibodies against the Omicron (BA.1) strain, indicating that the serum antibodies induced by delta S2-043 mRNA LNP immunization not only have a high level of neutralizing activity against the Delta strain, but also have a high level of cross-neutralizing activity against the Omicron strain.

[0096] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. A method for preparing delta S2-043 mRNA for the delta mutant strain of the new coronavirus, the sequence of which is shown in SEQ ID NO.

5.

2. A DNA molecule for preparing delta S2-043 mRNA, the sequence of which is shown in SEQ ID NO.

4.

3. Use of the delta S2-043 mRNA described in claim 1 in the preparation of an mRNA vaccine against the delta mutant strain of the new coronavirus.

4. Use of the DNA molecule described in claim 2 in the preparation of an mRNA vaccine against the delta mutant strain of the new coronavirus.

5. An mRNA vaccine against the delta mutant of the novel coronavirus, It is characterized in that The method is prepared from the delta S2-043 mRNA described in claim 1 and liposome particles.

6. A method for preparing an mRNA vaccine against the delta mutant of the novel coronavirus according to claim 5, It is characterized in that The following steps are involved: The delta S2-043 mRNA of claim 1 is dissolved in sodium citrate buffer to form an aqueous phase; The mass ratio of Dlin-MC3-DMA: DSPC: cholesterol: DMG-PEG2000 is 45-55: 7-12: 37-39: 1.2-1.8 to prepare an ethanol phase with anhydrous ethanol as solvent; The aqueous phase and the ethanol phase are coated according to a flow rate ratio of aqueous phase:ethanol phase of 2.5-4.5:1 and a total flow rate of 11-13 mL / min, and the nanolipid particles loaded with mRNA are collected and filtered and purified to obtain the result.

7. The preparation method according to claim 6, It is characterized in that The mass ratio of Dlin-MC3-DMA, DSPC, cholesterol and DMG-PEG2000 is 49-51:9-11:38-39:1.4-1.

6.

8. The preparation method according to claim 6 or 7, It is characterized in that Coating was performed at a flow rate ratio of aqueous phase:alcohol phase = 3:1 and a total flow rate of 12 mL / min.

9. Use of the mRNA vaccine against the delta mutant strain of the novel coronavirus as described in claim 5 in the preparation of immune drugs for preventing novel coronavirus infection caused by the Delta strain and the Omicron strain.

Citation Information

Patent Citations

  • SARS-CoV-2 coronavirus vaccine and preparation method thereof

    CN112618707A

  • Adjuvant of novel coronavirus vaccine, application of adjuvant and novel coronavirus bivalent recombinant vaccine

    CN113842455A

  • New coronavirus chimeric nucleic acid vaccines and uses thereof

    CN114989308A

  • Novel recombinant coronavirus S protein trimer vaccine composition and application thereof

    CN115845042A

  • MRNA for preventing and / or treating novel coronavirus, vaccine and preparation method and application thereof

    CN116410992A